Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 6/20 | 0.63 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250341 | 0.95 | IP6K1 (0.63) | IP6K1IP6K3IP6K2MAOBPARP1 | |
| SCHEMBL20897397 | 0.89 | IP6K1 (0.69) | IP6K1IP6K3IP6K2PARP1ROCK2 | |
| SCHEMBL17165598 | 0.85 | IP6K1 (0.63) | IP6K1IP6K3IP6K2PARP1ROCK2 | |
| SCHEMBL26109341 | 0.85 | IP6K1 (0.63) | IP6K1IP6K3IP6K2PARP1ROCK2 | |
| SCHEMBL31352813 | 0.85 | IP6K1 (0.63) | IP6K1IP6K3IP6K2PARP1ROCK2 | |
| SCHEMBL156504 | 0.84 | IP6K1 (0.62) | IP6K1IP6K3IP6K2PDPK1EGFR | |
| SCHEMBL1013586 | 0.84 | IP6K1 (0.62) | IP6K1IP6K3IP6K2PDPK1EGFR | |
| Hydrochloric Acid SCHEMBL27988350 | 0.82 | IP6K1 (0.60) | IP6K1IP6K3IP6K2PDPK1EGFR | |
| SCHEMBL4226040 | 0.82 | IP6K1 (0.57) | IP6K1IP6K3IP6K2MAOBPARP1 | |
| SCHEMBL14520678 | 0.82 | IP6K1 (0.63) | IP6K1IP6K3IP6K2PARP1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| EP-1163227-B1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-28 | — | — | EP | disclosed |
| CN-1150171-C | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for their preparation | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-05-19 | — | — | CN | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
| CN-1343201-A | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-04-03 | — | — | CN | disclosed |
| EP-1163227-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055141-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | IP6K1 4793/4885IP6K3 4721/4885IP6K2 4810/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | IP6K1 4793/4885IP6K3 4721/4885IP6K2 4810/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | IP6K1 4638/4885IP6K3 4688/4885IP6K2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.